ASP.. Acerus Pharmaceuticals

Acerus Announces Initiation of Strategic Review

Acerus Announces Initiation of Strategic Review

  • Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors

TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction.

The Board has struck a committee of independent directors to supervise this strategic review process. Ernst & Young Orenda Corporate Finance Inc. (“EY”) has been engaged as independent financial advisors to the Company. Parties interested in pursuing a transaction with Acerus should contact EY via one of the persons listed below to get further details and should plan to deliver a non-binding letter of interest no later than October 26, 2022.

Michael Hayes

Senior Vice-President

m

416 575 9089

Jatinder Wadhwa

Senior Vice-President

m

416 943 2063

Allen Yao

Vice-President

m

416 943 3470

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit and follow us on and .

Notice regarding forward-looking statements

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 14, 2022 that is available on . Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Company Contact

Investor Relations Contact

Chris Witty

Acerus Investor Relations

(646) 438-9385

        



EN
21/09/2022

Underlying

ASP..Acerus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acerus Pharmaceuticals

 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Update

Acerus Update TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP. The Transaction was approved by the Ontario Superior Court of Justice (Commercial List) (the “Court...

July 11, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Update

Acerus Update TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection pursuant to an order (the “Initial Order”) granted by the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). Pursuant to the Initial Order, Ernst & Young Inc. was appointed as monitor of the Company (in such capacity, the “Monitor”). As announced on March 14, 2023, the Court granted an order (the “SISP Ord...

May 26, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Announces Commencement of Court-Approved Sale and Investment So...

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an order (the “Initial Order”) issued under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”) by the Ontario Superior Court of Justice (the “Canadian Court”). Ernst & Young Inc. was appointed Monitor of Acerus (in such capacity, the “Monitor”). On February 3, 2023, the Initial Order was amended a...

March 14, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Files For CCAA Protection

Acerus Files For CCAA Protection TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). As previously disclosed on September 21, 2022, Acerus unde...

January 26, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Announces Resignation of Director

Acerus Announces Resignation of Director TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. About Acerus Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. Acerus’ shares trade on TSX under the symbol AS...

December 26, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch